Avelumab Injection + Methotrexate 1 GM Injection

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gestational Trophoblastic Neoplasias (GTN)

Conditions

Gestational Trophoblastic Neoplasias (GTN)

Trial Timeline

Feb 12, 2020 → Oct 12, 2028

NCT ID

NCT04396223

About Avelumab Injection + Methotrexate 1 GM Injection

Avelumab Injection + Methotrexate 1 GM Injection is a phase 1/2 stage product being developed by Merck for Gestational Trophoblastic Neoplasias (GTN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT04396223. Target conditions include Gestational Trophoblastic Neoplasias (GTN).

What happened to similar drugs?

5 of 10 similar drugs in Gestational Trophoblastic Neoplasias (GTN) were approved

Approved (5) Terminated (1) Active (4)

🔄somatropinEli LillyPhase 3

✅Insulin LISPRO + Insulin, Long-Acting and InsulinEli LillyApproved

❌Recombinant human growth hormone (r-hGH)MerckPhase 3

🔄Saizen® + Saizen®MerckPhase 3

✅Metformin + placeboNovo NordiskApproved

🔄Metformin XR plus placebo + Metformin XR plus liraglutideNovo NordiskPhase 3

✅Liraglutide + PlaceboNovo NordiskApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04396223	Phase 1/2	Recruiting	Feb 12, 2020	Oct 12, 2028	Gestational Trophoblastic Neoplasias (GTN)

Competing Products

18 competing products in Gestational Trophoblastic Neoplasias (GTN)

See all competitors

Product	Company	Stage	Hype Score
somatropin	Eli Lilly	Phase 3	40
Insulin LISPRO + Insulin, Long-Acting and Insulin	Eli Lilly	Approved	43
Camrelizumab plus apatinib CohortA + Camrelizumab plus apatinib Cohort B	Jiangsu Hengrui Medicine	Phase 2	42
Pembrolizumab Injection [Keytruda]	Merck	Phase 2	31
recombinant somatropin	Merck	Pre-clinical	26
Recombinant human growth hormone (r-hGH)	Merck	Phase 3	32
Saizen® + Saizen®	Merck	Phase 3	40
Metformin + placebo	Novo Nordisk	Approved	39
Metformin XR plus placebo + Metformin XR plus liraglutide	Novo Nordisk	Phase 3	40
Somapacitan + Norditropin®	Novo Nordisk	Phase 2	39
Liraglutide + Placebo	Novo Nordisk	Approved	43
Genotropin (PN-180,307) Somatropin + Control-no treatment	Pfizer	Phase 3	40
growth hormone	Pfizer	Pre-clinical	26
Somatropin	Pfizer	Pre-clinical	26
Somatropin	Pfizer	Pre-clinical	26
Genotropin (somatropin)	Pfizer	Approved	43
Omnitrope	Sandoz Group	Approved	40
Inhaled Technosphere Insulin	MannKind Corp	Phase 2/3	39